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SARS-CoV-2 is a virus. Viruses are very, very small particles that can stick to the surfaces of certain 
cells (called host cells) in our body. This 
sticking can only happen if the shape of 
a part of the virus surface matches the 
shape of a part of the cell surface. Only 
when this sticking happens efficiently 
can the virus particle get into the cell. 
Once inside, the genetic information in 
the virus particle (like the RNA in SARS-
CoV-2) is brought into operation by the 
biochemical processes of the cell. This 
results in redirection of these processes 
towards making and assembling many 
copies of the virus particle. These copies 
can then emerge from the infected cell 
(which often dies) and drift around. They 
can stick to many more new cells, not 
only starting the cycle all over again, but 
enlarging it.
Establishing infection
SARS-CoV-2 particles enter the body, by 
and large, through the nose and mouth 
into the airways. So the first cells they 
meet and infect are the cells lining these 
airways. The immune response of the body 
limits and contains these spots of infection. 
Large numbers of these infection spots can 
cause problems for the functioning of the 
airways. The virus particles can also spill 
over from these spots into the rest of the 
body, infecting cells in other parts, and 
increasing the problem.
Two factors help the virus infect us. 
The virus particle’s ability to stick 
very efficiently to target cells, and 
the usability of the virus RNA by the 
biochemical processes of many different 
cell types. The latter helps ensure that 
new virus particles will get made from 
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any cell type infected. Both are true of 
SARS-CoV-2 — it sticks very efficiently, 
and it can grow in most cell types. 
Two factors can hamper infection. The 
most obvious one is to prevent the 
virus from getting into the body. This is 
why measures like physical distancing, 
masks, and frequent hand-washing are 
recommended. Secondly, pre-existing 
immunity in the body, specifically 
against SARS-CoV-2, can prevent it, 
for example, from sticking efficiently 
to cells and entering them. This is what 
will happen, hopefully, with effective 
vaccination.
Infection symptoms  
and signs
Interestingly, most symptoms and signs 
of infection are, in fact, symptoms and 
signs of the body’s response to the 
infection! Since SARS-CoV-2 enters 
through the airways, most (though 
not all) of the earliest symptoms will 
relate to the airways. Infection of cells 
of the airway lining causes irritation 
and cough. Depending on whether 
the upper airway remains extensively 
infected or not, there may or may 
not be a ‘cold’ (which simply means 
such a lot of fluid comes out from 
the airways that it drips out from the 
nose and throat!). One of the many 
ways the body responds to the virus is 
by resetting its temperature control 
system, meaning fever. Since this re-
setting is quite variable, there may be 
differences in this symptom, ranging 
from mild to severe fever. Widespread 
growth of the virus in the airways and 
lungs as well as the body’s response 
to it affect the normal functioning of 
the airways and cause breathlessness. 
When both spill over, beyond the 
airways and lungs, other symptoms 
appear (see Fig. 1). These symptoms 
will vary depending on where in the 
body the virus happens to establish 
a foothold, and how widespread the 
body’s response is. In other words,  
the symptoms and signs of infection 
will then depend on which organs are 
most affected.
So far, there is no evidence that 
different genetic strains of the SARS-
CoV-2 virus tend to cause more or less 
severe illness. Currently, most of the 
variation in illness seems to be due to 
differences between people rather than 
the virus. Two categories of people are 
at higher risk of severe illness. One of 
these appears mostly to be associated 
with the existence of pre-existing 
changes in the body’s inflammatory 
responses. These are of the kind seen 
in obesity, type 2 diabetes, heart 
disease, hypertension, chronic kidney 
or liver diseases, in the elderly, and 
(in a double whammy) in people with 
pre-existing chronic airway-related 
illnesses. As of now, there is little 
evidence that asthma in particular 
predisposes to severe COVID-19 
illness, although clinical researchers 
are looking for such associations. A 
second category is of people with poor 
immune responses, such as cancer 
patients under chemotherapy. 
The general indication from evidence 
seems to be that COVID-19 affects 
children and young adults less severely 
than it affects the elderly, although 
the symptoms seem to be similar in all 
groups. (There are rare instances of a 
quite distinct illness pattern in children, 
which is not yet well understood.) 
However, this is not the same as 
‘children being at low risk’. They will 
and do get infected. Also, while their 
own illness may be mild, children can 
certainly spread the infection to other 
people, such as their grandparents, who 
are at higher risk. It is useful to keep in 
mind that a large proportion of SARS-
CoV-2 infections are ‘asymptomatic’, 
meaning without any symptoms at 
all. Among the infected people who 
do develop symptoms, cough is the 
commonest; only about a fifth of such 
people show no cough at all. The next 
commonest is fever, although about a 
third of infected people with symptoms 
show little or no fever. Breathlessness is 
the commonest symptom in the severe 
form of COVID-19. Screening for fever 
at travel checkpoints is useful, but it 
is likely that the spread of the virus 
Fig. 1. The symptoms and signs of COVID-19 infection will vary depending on where in the 
body the virus happens to establish a foothold, and how widespread the body’s response is. 
Credits: Adapted from an image by Mikael Häggström, Wikimedia Commons. URL: https://commons.
wikimedia.org/wiki/File:Symptoms_of_coronavirus_disease_2019.svg. License: CC-0. 
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from an infected individual starts a few 
days before that individual develops 
symptoms.
Fatality rates 
Knowing exact numbers for 
measurements such as death rates for 
a pandemic is only possible when we 
look back at it. The so-called ‘infection 
fatality rate’ is the proportion of death 
amongst all infected people. Since 
so many SARS-CoV-2 infections are 
asymptomatic, this number is impossible 
to determine accurately at the moment. 
We need much more evidence of 
‘exposure’ from surveys that will take a 
long time to collect. The so-called ‘case 
fatality rate’, which is widely discussed 
as being between 2-8%, is also quite 
inaccurate. This rate is the proportion 
of death amongst all infected and 
symptomatic ‘cases’, but what degree 
of severity is to be called a ‘case’ varies 
a lot from place to place and from time 
to time. Nonetheless, what we do know 
is that SARS-CoV-2 infection is not as 
dangerous as other coronaviruses we 
have met earlier, such as SARS-CoV or 
MERS-CoV (see Box 1). In fact, all the 
very approximate estimates and guesses 
of the infection fatality rate of SARS-
CoV-2 put the number at much below 
1%. Even among the categories of 
people at extremely high risk of severe 
COVID-19 illness, the eventual infection 
fatality rate is unlikely to exceed 5%.
However, nobody can predict, with 
absolute accuracy, what the course 
of illness will be in an individual. All 
our information is statistical and 
based on likelihoods, not guarantees. 
Good medical facilities will make the 
difference between life and death in 
people with severe illness. Severe illness 
is characterised by extensive lung 
involvement, with severe breathlessness 
and/or symptoms of other organs being 
affected. At such stages, if comparable 
medical-health facilities are available, 
the outcomes for severely ill COVID-19 
patients are likely to be the same 
everywhere in the world. However, 
medical facilities are not comparable 
across the world and are, in fact, even 
less comparable between the well-off 
and the poor in the same place. 
Parting thoughts
In this context, it is important to keep 
in mind that SARS-CoV-2 infection is 
not a major individual risk. In other 
words, every individual who is infected 
is not at major risk of severe illness, let 
alone of death. The spread of infection 
is a problem because if enough people 
get infected at the same time, then 
even the small proportion of severely 
ill people will be in large numbers 
and hospitals will be overwhelmed. 
This spread can be reduced by 
quickly identifying individual cases in 
communities, careful and rapid tracing 
of their contacts, providing every 
kind of support to infected/exposed 
individuals during their isolation, 
and increasing our public hospital 
capacity. Isolation needs to be seen 
as an action that infected or exposed 
individuals undertake for the good of 
the community, and not for their own 
sakes. This needs to be coupled with a 
cultural acceptance by society at large 
of a new norm of physical (NOT ‘social’!) 
distancing along with the use of 
face-and-nose-coverings and frequent 
hand cleaning. Clearly, we — both the 
government and society — are failing 
miserably on most (if not all) of these 
fronts, and have simply been using 
versions of the so-called ‘lockdown’, 
including but not limited to keeping 
schools closed, as a (bad) substitute.
Box 1. How is COVID-19 different from other viral infections? 
COVID-19 is likely more ‘dangerous’ than seasonal flu or 
influenza, in the sense that its ‘infection fatality rate’ is 
likely to turn out to be higher. While the viruses causing 
these infections are likely to be equally contagious, how 
‘contagious’ a virus actually is will also depend on how 
susceptible the population is. Many of us are at least a 
little bit resistant to seasonal flu because of prior exposure 
to similar viruses, but that does not seem to be the case 
with COVID-19. This is likely to increase the actual rate of 
spread of SARS-CoV-2. Once again, this is why, even though 
COVID-19 infection does not put every individual who is 
infected at major risk of severe illness, it is a societal problem. 
If enough people get infected at the same time, then even 
the small proportion of severely ill people will be in large 
numbers and overwhelm hospitals.
Measles, chickenpox and mumps all enter the body through 
the nose and mouth, but they spread outside these areas 
of the body quite often. These viruses are all MUCH more 
contagious than either flu or COVID-19. Because they 
are so common, many adults tend to have met them and 
developed resistance. Therefore, most actual cases are in 
children. Measles can cause death about as frequently as 
seasonal flu does, while chickenpox and mumps are much 
less lethal than that.
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• That SARS-CoV-2 sticks efficiently to target cells and grows in most cell types in the human 
body aids its ability to infect us. 
• Preventing entry to the virus (through physical distancing, use of face masks, and hand hygiene), 
and developing immunity through effective vaccination can hamper SARS-CoV-2 infection. 
• The symptoms and signs of COVID-19 infection vary depending on where in the body the virus 
happens to establish a foothold, and how widespread the body’s response is.
• Most variations in illness seem to be due to differences between people rather than the virus. 
People with pre-existing changes in the body’s inflammatory responses and poor immune 
responses are more susceptible to severe illness. 
• Evidence suggests that COVID-19 affects children and young adults less severely than it affects 
the elderly. Children can spread the infection to people at risk, including their grandparents. 
• It is difficult to know exact numbers for measurements such as death rates at this stage of the 
pandemic. But eventual infection fatality rates are unlikely to exceed 5% even among people at 
extremely high risk of severe COVID-19 illness. 
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